Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 14/20 | 0.76 |
| ▸ | CNR1 | P21554 | 2/20 | 0.63 |
| ▸ | CNR2 | P34972 | 1/20 | 0.62 |
| ▸ | MAOA | P21397 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 1/20 | 0.58 |
| ▸ | FPR2 | P25090 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.55 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.54 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2433648 | 0.87 | CASR (1.00) | CASRCNR1CNR2MTNR1AMTNR1B | |
| SCHEMBL2430546 | 0.85 | CASR (0.76) | CASRCNR1CNR2MEN1KMT2A | |
| SCHEMBL2430084 | 0.85 | CASR (1.00) | CASRCNR1CNR2MEN1KMT2A | |
| SCHEMBL2433839 | 0.85 | CASR (1.00) | CASRCNR1CNR2MEN1KMT2A | |
| SCHEMBL2433310 | 0.83 | CASR (0.78) | CASRMTNR1AMTNR1B | |
| SCHEMBL2434172 | 0.82 | CASR (1.00) | CASRCNR1CNR2FPR2MEN1 | |
| SCHEMBL2431422 | 0.81 | CASR (0.69) | CASRCNR1CNR2MEN1KMT2A | |
| SCHEMBL11050914 | 0.81 | CNR1 (0.66) | CNR1MAOAMAOBFPR2MEN1 | |
| SCHEMBL4897395 | 0.79 | CNR1 (0.74) | CNR1MAOAMAOBFPR2KMT2A | |
| SCHEMBL2432001 | 0.78 | CASR (1.00) | CASRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2366698-A1 | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | Galapagos SAS (FR) | 2011-09-21 | — | — | EP | disclosed |
| US-20080125424-A1 | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | GALAPAGOS SAS (FR) | 2008-05-29 | — | — | US | disclosed |
| US-20080125424-A1 | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | GALAPAGOS SAS (FR) | 2008-05-29 | — | — | US | disclosed |
| US-20080125424-A1 | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | GALAPAGOS SAS (FR) | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125424-A1 | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | UTS2R, CASR, GPR17 | CASR 2/4885CNR1 94/4885CNR2 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.